This is an overview of the USAID/Indonesia FY 2023 Tuberculosis (TB) Roadmap, implemented with the FY 2022 budget.

TABLES

The following tables illustrate the distribution by technical area of the USAID TB budget for Indonesia that will be used for the implementation of Indonesia’s FY23 TB Roadmap (Table 1) and the core indicators that will be used to monitor implementation of Indonesia’s TB Roadmap and the country's progress towards the United Nations General Assembly High-Level Meeting on TB targets (UNGA targets) (Table 2).

Table 1: USAID Budget for Philippines per Technical Area

Technical AreaUSAID TB budgetUSAID Percentage of TB budget
REACH$8,619,61139%
CURE$4,740,07822%
PREVENT$6,358,16429%
SUSTAINABLE SYSTEMS$2,281,14710%
TOTAL BUDGET:$22,000,000100%

Table 2: TB Core Indicators in Zimbabwe from 2015-2021 and Target of 2022

#Name20152016201720182019202020212022*
REACH: Increased DS- and DR-TB case notification
1TB Detection39.4%43.3%52.4%66.7%67.0%46.6%44.64%UNGA target: 707,900
2Bacteriological Diagnosis Coverage (Pulmonary TB)64.2%58.9%54.0%49.7%52.0%52%56.05% 
3Childhood TB Notifications28,41232,60252,94460,89270,09235,46141,968UNGA target: 70,000
4Drug-Resistant TB Notifications2,1732,7575,1219,11811,4967,9218,268UNGA target: 21,900
5Private Sector TB Notifications31,00237,54158,633101,839109,21674,54798,308 
6Contact Investigation Coverage**--------3.0%3%97.89% 
CURE: High treatment success rate in DS- and DR-TB
7TB Treatment Success Rate***85.1%85.8%84.7%83.0%83.0%86.08%  
8Drug-Resistant TB treatment Success Rate*****46.9%47.1%45.0%47%45.81%   
PREVENT: Prevent TB transmission and development
9TPT Coverage59187713,76121,84127,95919,6495,486UNGA target: 587,600
SUSTAINABLE SYSTEMS: Commitment and sustainability
10Proportion of Domestic Financing for TB------68.0%38.0%59%39.67% 

*Projected Targets: These represent the United Nations General Assembly High-Level Meeting targets (UNGA targets)

**Contact Investigation Coverage: based on limited available data .
***TB Treatment Success Rate: newest data for 2020 cohort reported.
****Drug-Resistant TB Treatment Success Rate: newest data for 2019 cohort reported.